2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsGlucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy
Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.Peer-Reviewed Original ResearchConceptsGaucher disease type 1Monoclonal gammopathyAntigenic targetsClonal immunoglobulinDisease type 1B cell activationAccumulation of glucosylceramideGD1 patientsImmunogenic lipidsMetabolic inflammationMultiple myelomaGD patientsHigh riskTarget antigenCell activationImmunoglobulin typeGammopathyType 1PatientsGenetic deficiencyAge-related phenotypesSaposin CClonal IgLysosomal glucocerebrosidaseGlcSph
2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy
Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 2019, 5 PMID: 31013254, PMCID: PMC6629164, DOI: 10.1172/jci.insight.127807.Peer-Reviewed Original ResearchMeSH KeywordsBone MarrowCell Transformation, NeoplasticFemaleGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 1-alphaHumansImmunity, InnateImmunologic MemoryImmunologic SurveillanceIntercellular Signaling Peptides and ProteinsMaleMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaMyeloid CellsPrecancerous ConditionsRNA-SeqSingle-Cell AnalysisStem CellsT-LymphocytesTumor MicroenvironmentConceptsMemory T cellsSingle-cell transcriptome analysisT cellsMyeloid cellsMyeloma patientsTerminal effector differentiationImmune cellsHealthy donorsProlonged dormancyTranscriptome analysisBone marrowBone marrow immune cellsStem-like cellsStem-like T cellsAge-matched healthy donorsDistinct genomic profilesResident T cellsSingle immune cellsT cell compartmentBone marrow plasmaCell compartmentGenomic profilesCancer cellsPreneoplastic gammopathyImmune microenvironmentThe impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)
Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsAntimicrobial StewardshipFebrile NeutropeniaFemaleHematopoietic Stem Cell TransplantationHumansMaleMedication Therapy ManagementMethicillin-Resistant Staphylococcus aureusMiddle AgedNoseRetrospective StudiesStaphylococcal InfectionsTime FactorsVancomycinYoung AdultConceptsHematopoietic stem cell transplant recipientsPost-intervention cohortFebrile neutropeniaVancomycin useVancomycin discontinuationStewardship teamRetrospective analysisMultimodal approachStem cell transplant recipientsResistant Gram-positive organismsResistant Gram-positive infectionsAntibiotic stewardship teamDiscontinuation of vancomycinEvidence of pneumoniaPost-implementation cohortPrevious MRSA infectionCell transplant recipientsGram-positive infectionsNasal swab collectionEmpiric vancomycinFN patientsVancomycin ordersVancomycin usageHSCT recipientsTransplant recipients
2018
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. Journal Of Clinical Investigation 2018, 128: 715-720. PMID: 29309048, PMCID: PMC5785243, DOI: 10.1172/jci96798.Peer-Reviewed Original ResearchConceptsCombination checkpoint blockadeB cell changesB cellsCheckpoint blockadeCell changesCombination immune checkpoint blockadeB-cell receptor sequencingRisk of irAEsImmune checkpoint blockadeCell receptor sequencingB cell activationTreatment-induced changesCCB therapyAdverse eventsPD1 expressionPD1 receptorGrade 3PatientsCell activationEarly changesSingle-cell RNA sequencingTherapyPreemptive strategyCancer therapyIrAEs
2015
Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart
Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology 2015, 33: 3689-3690. PMID: 26371139, DOI: 10.1200/jco.2015.63.2224.Peer-Reviewed Original Research